Journal of Clinical & Experimental OncologyISSN: 2324-9110

Reach Us +1 850 900 2634
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Review Article, J Clin Exp Oncol Vol: 6 Issue: 1

Chemotherapy for Patients with Renal Dysfunction

Koichi Suyama1*, Yuji Miura2, Toshimi Takano2 and Hirotaka Iwase1,3
1Kumamoto University Hospital Cancer Center, Kumamoto, Japan
2Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan
3Department of Breast and Endocrine Surgery, Kumamoto University, Kumamoto, Japan
Corresponding author : Koichi Suyama
Kumamoto University Hospital Cancer Center, Graduate School of Life Sciences, Kumamoto University, Japan
Tel: +81-96-373-5599
E-mail: [email protected]
Received: December 23, 2016 Accepted: January 09, 2017 Published: January 16, 2017
Citation: Suyama K, Miura Y, Takano T, Iwase H (2017) Chemotherapy for Patients with Renal Dysfunction. J Clin Exp Oncol 6:1. doi: 10.4172/2324-9110.1000174

Abstract

Significant progress has been made in systemic chemotherapies for advanced cancer patients. Historically, the main anticancer drugs were cytotoxic agents, but recently, other agents such as molecularly-targeted therapies and immune checkpoint inhibitors have been introduced into clinical practice, and these agents have begun to achieve mainstream usage. The rapid development of novel anticancer drugs has forced clinicians to consider the effects of these chemotherapy agents in high-risk patients with liver or renal dysfunction, those undergoing dialysis and the elderly. Currently, there are no clear guidelines describing the best practices for anticancer drug administration in patients with renal dysfunction. However, the theory that renal dysfunction affects the ability of patients to cope with anticancer therapies is understandable compared with liver dysfunction or other risk factors. That is why there has always been an indication for dose adjustments for patients with renal dysfunction. In this review, recommended dose adjustments in cases of renal dysfunction are discussed based on the latest information on anticancer drugs.

Keywords: Chemotherapy; Anticancer drug; Renal dysfunction;Dose adjustment

Track Your Manuscript

Share This Page

Media Partners